TABLE 1.
The list of patients with brain gliomas evaluated in the present study with their basic characteristics (histopathological diagnosis, WHO grade, gender, age, and overall survival time), as well as promoter DNA methylation of analyzed genes (SFRP1, SFRP2, RUNX3, CBLN4, INA, MGMT, RASSF1A)
| Indication | |||||||
|---|---|---|---|---|---|---|---|
| Methylation level [%] | 0 | >0, ≤5 | >5, ≤10 | >10, ≤25 | >25, ≤50 | >50, ≤75 | >75, ≤100 |
| No | Histopathological classification | WHO grade | Gender | Age [years] | Overall survival [months] | SFRP1 | SFRP2 | RUNX3 | CBLN4 | INA | MGMT | RASSF1A |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GBM | IV | M | 60 | 8 | >10, ≤25% | >0, ≤5% | >0, ≤5% | >0, ≤5% | >0, ≤5% | 0% | >10, ≤25% |
| 2 | GBM | IV | M | 58 | 17 | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 3 | GBM | IV | M | 58 | 10 | >0, ≤5% | >0, ≤5% | 0% | 0% | 0% | 0% | 0% |
| 4 | GBM | IV | M | 58 | 9 | >10, ≤25% | >0, ≤5% | >0, ≤5% | >0, ≤5% | 0% | 0% | >10, ≤25% |
| 5 | GBM | IV | M | 56 | nk | >10, ≤25% | 0% | 0% | >0, ≤5% | >5, ≤10% | 0% | >10, ≤25% |
| 6 | GBM | IV | M | 54 | 16 | >25, ≤50% | >0, ≤5% | 0% | >0, ≤5% | 0% | 0% | 0% |
| 7 | GBM | IV | M | 47 | 10 | 0% | >0, ≤5% | >0, ≤5% | 0% | 0% | 0% | >0, ≤5% |
| 8 | GBM | IV | M | 45 | 21 | 0% | nk | 0% | 0% | 0% | 0% | 0% |
| 9 | GBM | IV | M | 41 | nk | >25, ≤50% | 0% | 0% | >0, ≤5% | 0% | 0% | 0% |
| 10 | GBM | IV | F | 70 | 3 | >25, ≤50% | 0% | 0% | 0% | 0% | >25, ≤50% | 0% |
| 11 | GBM | IV | F | 65 | nk | >10, ≤25% | 0% | 0% | 0% | >0, ≤5% | 0% | >25, ≤50% |
| 12 | GBM | IV | F | 60 | 36 | >25, ≤50% | 0% | 0% | >10, ≤25% | >0, ≤5% | >10, ≤25% | >25, ≤50% |
| 13 | GBM | IV | F | 52 | nk | >0, ≤5% | >0, ≤5% | 0% | 0% | 0% | >10, ≤25% | 0% |
| 14 | GBM recidivans | IV | M | 31 | 8 | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 15 | GBM recidivans | IV | M | 31 | 8 | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 16 | GBM recidivans | IV | F | 64 | nk | >10, ≤25% | 0% | >10, ≤25% | 0% | 0% | 0% | 0% |
| 17 | GBM recidivans | IV | F | 60 | nk | 0% | 0% | 0% | 0% | 0% | >0, ≤5% | >0, ≤5% |
| 18 | GBM recidivans | IV | F | 59 | 4 | 0% | >0, ≤5% | 0% | 0% | >0, ≤5% | 0% | 0% |
| 19 | GBM recidivans | IV | F | 50 | nk | >10, ≤25% | 0% | 0% | 0% | 0% | >5, ≤10% | 0% |
| 20 | Gliosarcoma | IV | F | 75 | 10 | >10, ≤25% | >5, ≤10% | >25, ≤50% | >0, ≤5% | >0, ≤5% | >10, ≤25% | >0, ≤5% |
| 21 | Anaplastic astrocytoma | III | M | 83 | nk | >25, ≤50% | >0, ≤5% | 0% | >0, ≤5% | >0, ≤5% | >10, ≤25% | >10, ≤25% |
| 22 | Anaplastic astrocytoma | III | M | 60 | 10 | 0% | >0, ≤5% | 0% | 0% | >0, ≤5% | >25, ≤50% | >10, ≤25% |
| 23 | Anaplastic astrocytoma | III | M | 59 | nk | >10, ≤25% | >0, ≤5% | >5, ≤10% | >0, ≤5% | >0, ≤5% | 0% | 0% |
| 24 | Anaplastic astrocytoma | III | M | 58 | 11 | 0% | 0% | >5, ≤10% | 0% | 0% | 0% | >0, ≤5% |
| 25 | Anaplastic astrocytoma | III | M | 45 | nk | >5, ≤10% | >0, ≤5% | >5, ≤10% | >0, ≤5% | >0, ≤5% | 0% | >10, ≤25% |
| 26 | Anaplastic astrocytoma | III | M | 29 | 18 | >25, ≤50% | >0, ≤5% | >0, ≤5% | >0, ≤5% | 0% | 0% | >5, ≤10% |
| 27 | Anaplastic astrocytoma | III | F | 73 | nk | >25, ≤50% | >5, ≤10% | >10, ≤25% | >0, ≤5% | >10, ≤25% | >50, ≤75% | >0, ≤5% |
| 28 | Anaplastic astrocytoma | III | F | 66 | nk | >10, ≤25% | >0, ≤5% | >5, ≤10% | 0% | >0, ≤5% | 0% | 0% |
| 29 | Anaplastic astrocytoma | III | F | 48 | nk | 0% | >0, ≤5% | >0, ≤5% | >0, ≤5% | >0, ≤5% | 0% | 0% |
| 30 | Anaplastic astrocytoma | III | F | 48 | nk | 0% | 0% | 0% | >0, ≤5% | >0, ≤5% | >0, ≤5% | 0% |
| 31 | Anaplastic astrocytoma | III | F | 41 | 42 | 0% | 0% | 0% | 0% | 0% | >10, ≤25% | >50, ≤75% |
| 32 | Anaplastic astrocytoma recidivans | III | M | 53 | nk | 0% | >0, ≤5% | 0% | 0% | 0% | 0% | >25, ≤50% |
| 33 | Anaplastic astrocytoma recidivans | III | F | 47 | 8.5 | >25, ≤50% | 0% | 0% | >0, ≤5% | 0% | >10, ≤25% | >50, ≤75% |
| 34 | Astrocytoma gemistocyticum in astrocytoma angioplasticum vertens | III | F | 28 | nk | 0% | 0% | 0% | 0% | 0% | >10, ≤25% | >25, ≤50% |
| 35 | Glioma anaplasticum NOS | III | M | 58 | 23 | 0% | 0% | 0% | 0% | 0% | >10, ≤25% | >25, ≤50% |
| 36 | Glioma anaplasticum recidivans | III | M | 59 | 3 | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 37 | Oligoastrocytoma anaplasticum | III | M | 29 | 23 | >25, ≤50% | 0% | 0% | 0% | 0% | >10, ≤25% | >50, ≤75% |
| 38 | Oligoastrocytoma anaplasticum | III | F | 77 | 3.5 | >25, ≤50% | 0% | 0% | >0, ≤5% | >0, ≤5% | 0% | >25, ≤50% |
| 39 | Clear cell ependymoma | III | F | 19 | 3 | 0% | >0, ≤5% | 0% | 0% | 0% | 0% | >25, ≤50% |
| 40 | Astrocytoma fibrillare partim protoplasmaticum | II | M | 51 | 12.5 | >10, ≤25% | >0, ≤5% | 0% | >0, ≤5% | 0% | >10, ≤25% | >50, ≤75% |
| 41 | Astrocytoma fibrillare partim gemistocyticum | II | M | 37 | nk | >10, ≤25% | 0% | 0% | 0% | 0% | >0, ≤5% | >50, ≤75% |
| 42 | Astrocytoma fibrillare | II | F | 38 | 18 | >10, ≤25% | 0% | >0, ≤5% | nk | nk | >0, ≤5% | >10, ≤25% |
| 43 | Oligodendroglioma isomorphum | II | M | 59 | 6 | >25, ≤50% | >0, ≤5% | >5, ≤10% | 0% | 0% | >10, ≤25% | >50, ≤75% |
| 44 | Ganglioglioma | II | M | 37 | nk | >25, ≤50% | nk | >0, ≤5% | 0% | 0% | >10, ≤25% | >25, ≤50% |
| 45 | Subependymal giant cell astrocytoma | I | M | 23 | 24 | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 46 | Ganglioglioma | I | M | 16 | nk | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
The percentage of methylation is expressed with different color intensity (lowest DNA methylation level—brightest color, highest—the darkest one). Indication "nk", not known—indicates samples for which the results were not obtained or were ambiguous.